1. Home
  2. GTE vs CRDF Comparison

GTE vs CRDF Comparison

Compare GTE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gran Tierra Energy Inc.

GTE

Gran Tierra Energy Inc.

N/A

Current Price

$8.11

Market Cap

209.3M

Sector

Energy

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.81

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTE
CRDF
Founded
2003
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.3M
130.7M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
GTE
CRDF
Price
$8.11
$1.81
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
871.2K
663.7K
Earning Date
03-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
$374,460,000.00
$365,993.00
Revenue This Year
$3.67
N/A
Revenue Next Year
$0.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
41.99
49.61
52 Week Low
$3.09
$1.48
52 Week High
$8.84
$4.56

Technical Indicators

Market Signals
Indicator
GTE
CRDF
Relative Strength Index (RSI) 64.45 44.22
Support Level $3.83 $1.51
Resistance Level N/A $2.05
Average True Range (ATR) 0.56 0.12
MACD 0.09 0.01
Stochastic Oscillator 75.02 1.96

Price Performance

Historical Comparison
GTE
CRDF

About GTE Gran Tierra Energy Inc.

Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: